Antibe Therapeutics, Inc.

Antibe Therapeutics, Inc.

March 01, 2005 07:00 ET

Antibe Therapeutics Announces Positive Proof-of-Concept Pre-Clinical Data on its Mesalamine Derivatives for Inflammatory Bowel Disease



MARCH 1, 2005 - 07:00 ET

Antibe Therapeutics Announces Positive
Proof-of-Concept Pre-Clinical Data on its Mesalamine
Derivatives for Inflammatory Bowel Disease

CALGARY, ALBERTA--(CCNMatthews - March 1, 2005) - Studies performed by a
leading European researcher demonstrate a marked increase in potency and
efficacy of Antibe Therapeutics' lead compounds for inflammatory bowel
disease (IBD). Professor Stefano Fiorucci, of the University of Perugia,
compared the effects of ATB-428 and ATB-429 to those of mesalamine, the
first-line therapy for IBD. "In studies in rats with colitis, we
observed not only a significant increase in potency of the two Antibe
compounds as compared to mesalamine, but also some remarkable additional
anti-inflammatory effects", remarked Prof. Fiorucci. "Most notably, the
Antibe compounds potently suppressed the production of several
pro-inflammatory cytokines known to play important roles in human IBD,
including tumour necrosis factor, interleukin 12 and interferon gamma.
Mesalamine alone did not alter the production of these cytokines".

ATB-428 and ATB-429 are derivatives of mesalamine (5-amino salicylic
acid) developed by Antibe. The world market for mesalamine is
approximately US$500 million. While producing very few side effects,
mesalamine is limited in its utility for treating moderate to severe IBD
by low potency.

John Wallace, President & CEO of Antibe, commented: "The data generated
in Prof. Fiorucci's laboratory provide proof-of-concept for Antibe's
drug development strategy. By modifying the structure of existing drugs,
such as mesalamine, we can significantly enhance potency and greatly
expand the scope of anti-inflammatory activities. The ability of ATB-428
and ATB-429 to potently suppress the production of cytokines such as
TNF-alpha and IL-12 is particularly exciting, given the role of these
substances in the pathogenesis of IBD."

About Antibe Therapeutics, Inc.

Antibe (pronounced 'on-teeb') Therapeutics -
- is a privately held early stage drug development company headquartered
in Calgary, Canada with affiliate laboratories in the USA, United
Kingdom, Italy and Brazil. The Company's pipeline consists of drugs
targeting serious chronic diseases, including inflammatory bowel
disease, erectile dysfunction, irritable bowel syndrome, pulmonary
hypertension and various complications of diabetes.

Antibe's drug development platform involves the assimilation of small
vasoactive/immunomodulatory components to existing drugs to generate new
chemical entities that are significantly improved over the parent
molecules and/or serve unmet medical needs.

With more than 50 years combined experience in the pharmaceutical and
biotech sectors, Antibe's senior management team has a well-defined
track record in the development of anti-inflammatory and vasoactive
drugs, for which they have received approval from various regulatory
boards inclusive of the US FDA.

For further information regarding ATB-428, ATB-429 and other drug
development programs, please see contacts below.


Contact Information